CDEK
← All drugs Report issue

ramipril

Trade name: altace

Small moleculeapproved

Approved

Jan 28, 1991

Ramipril (sold under the brand name Altace ) is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitors. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril is indicated for the treatment of hypertension, to lower blood pressure; also used to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes; in addition, this drug is used to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. — NCATS

Clinical trial activity

165 trials · 156 clinical orgs · 25 marketing orgs

Phase 1
25
Phase 2
60
Phase 3
45
Phase 4
57

Earliest trial started Feb 1, 1995 (NCT04364139)

Timeline

1990s

  1. Jan 28, 1991

    Earliest FDA Approval

  2. Jan 28, 1991

    King Pharmaceuticals — NDA Secondary Org

  3. Jan 1, 1995

    Earliest Phase 3 Sponsor(trial)

2000s

  1. Jan 1, 2000

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2004

    Teva — Earliest Phase 1 Sponsor(trial)

  3. Oct 24, 2005

    Watson Pharmaceuticals — Marketing Organization

  4. Feb 27, 2007

    Pfizer — NDA Secondary Org

  5. Jun 9, 2008

    Lupin — Marketing Organization

  6. Jun 18, 2008

    Actavis — Marketing Organization

  7. Jun 18, 2008

    Chartwell Pharmaceuticals — Marketing Organization

  8. Jun 18, 2008

    Dr. Reddy's Laboratories — Marketing Organization

  9. Jun 18, 2008

    Teva — Marketing Organization

  10. Jun 18, 2008

    West-Ward Pharmaceutical — Marketing Organization

  11. Jun 18, 2008

    Hikma — Marketing Organization

  12. Jun 18, 2008

    Fosun — Marketing Organization

  13. Jun 18, 2008

    ANDA Repository — Marketing Organization

  14. Jun 18, 2008

    Senores Pharms — Marketing Organization

  15. Jun 20, 2008

    Corepharma — Marketing Organization

  16. Jun 20, 2008

    Impax Laboratories — Marketing Organization

  17. Aug 7, 2008

    Cipla — Marketing Organization

  18. Sep 2, 2008

    Zydus Discovery DMCC — Marketing Organization

  19. Mar 6, 2009

    Ranbaxy — Marketing Organization

2010s

  1. Jun 8, 2011

    Aurobindo Pharma — Marketing Organization

  2. Jun 30, 2011

    Mylan — Marketing Organization

  3. Jun 30, 2011

    Natco Pharma — Marketing Organization

  4. Apr 15, 2014

    Accord Research — Marketing Organization

  5. Dec 2, 2015

    Apotex — Marketing Organization

2020s

  1. Jul 23, 2025

    Perrigo — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedJan 28, 1991

Chemistry & pharmacology

Loading structure…

SMILES

C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(O)=O
Mol. weight
388.4574 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Black box warningProdrug

Sources

Also known as

  • (2s-(1(r*(r*)),2alpha,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
  • (2s-(1(r*(r*)),2alpha,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
  • altace
  • altace
  • altace
  • altace
  • altace (tn)
  • altace (tn)
  • hoe498
  • hoe498
  • hoe498
  • hoe498
  • hoe498
  • hoe498
  • hoe-498
  • hoe-498
  • hoe-498
  • lopace
  • ramipril
  • ramipril
  • ramipril
  • ramipril
  • ramipril
  • ramipril
  • ramipril
  • ramipril
  • ramipril
  • ramiprilum
  • ramiprilum
  • rampiril
  • ranace
  • ranipril
  • tritace
  • tritace
  • tritace

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07259512Phase 4Jun 30, 2025Universitas Sebelas Maret
NCT06562582Phase 4Sep 1, 2024Vastra Gotaland Region
NCT06304896Phase 1May 1, 2024Arab Contractors Medical Centre
NCT07184918N/AFeb 1, 2024Tanta University
NCT07023016Phase 2/Phase 3 (Phase 3)Nov 1, 2023Cairo University, National Heart Institute, Egypt
NCT06104423Phase 4Oct 2, 2023Menarini Group, University of Roma La Sapienza
NCT05849766Phase 3Apr 27, 2023Beni Suef University, National Heart Institute, Egypt, October 6 University
NCT05685277Phase 1Dec 28, 2022Ligand Research, LLC, Pharmtechnology LLC
NCT05508035Phase 3Sep 15, 2022John Paul II Hospital, Krakow
NCT05438316Phase 1Jun 17, 2022Ligand Research, LLC, Pharmtechnology LLC
NCT05232370Phase 2Jan 1, 2022Unidad de Investigacion Medica en Enfermedades Renales
NCT05133050N/AJan 1, 2022Jiao Tong University
NCT05030818Phase 4Nov 1, 2021Hospital de Cabueñes, Gijon, Hospital Universitario Central de Asturias
NCT05271448N/AJun 1, 2021An-Najah National University
NCT04591210Phase 3Oct 30, 2020University of Ottawa
NCT04366050Phase 2Apr 30, 2020Pfizer, University of California, San Diego
NCT04173949Phase 3Dec 15, 2019Emek Medical Center
NCT04588935Phase 2Jul 1, 2019Government of Belarus
NCT03991910Phase 3Jun 17, 2019University of Indonesia
NCT03715998Phase 2Jun 4, 2019Quantum Genomics SA, Sorbonne University
Showing 20 of 165 trials
Page 1 / 9

Organizations

Research & Development (156)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Boehringer IngelheimFor profit121141998
NovartisFor profit121142006
SanofiFor profit11832000
PfizerFor profit8442001
Vanderbilt UniversityAcademic/Hospital7742005
Ferrer Internacional S.A.For profit6422009
CEDRA Clinical ResearchFor profit5022004
McMaster UniversityAcademic/Hospital5122001
National Heart, Lung, and Blood Institute (NHLBI)Government5122000
Mario Negri InstituteAcademic/Hospital4222009
ActavisFor profit3312004
Cairo UniversityAcademic/Hospital3012018
Heart and Stroke Foundation of CanadaAcademic/Hospital3212001
Saglik Bilimleri UniversitesiAcademic/Hospital3312006
SFBC AnapharmFor profit3012004
St. John's Research InstituteAcademic/Hospital3222007
TevaFor profit3312004
AstraZenecaFor profit2122005
AventisFor profit2011998
Beni Suef UniversityAcademic/Hospital2122019
156 organizations
Page 1 / 8

Marketing (29)

OrganizationOrg typeRelationshipDate
ANDA RepositoryFor profitMKTGJun 18, 2008
Accord ResearchFor profitMKTGApr 15, 2014
ActavisFor profitMKTGJun 18, 2008
ApotexFor profitSYNJun 20, 2008
ApotexFor profitMKTGDec 2, 2015
Aurobindo PharmaFor profitMKTGJun 8, 2011
Chartwell PharmaceuticalsFor profitSYNJun 18, 2008
Chartwell PharmaceuticalsFor profitMKTGJun 18, 2008
CiplaFor profitMKTGAug 7, 2008
CorepharmaFor profitMKTGJun 20, 2008
Dr. Reddy's LaboratoriesFor profitMKTGJun 18, 2008
FosunFor profitMKTGJun 18, 2008
HikmaFor profitMKTGJun 18, 2008
HikmaFor profitSYNJun 18, 2008
HoechstFor profitNDA—
Impax LaboratoriesFor profitMKTGJun 20, 2008
King PharmaceuticalsFor profitNDA2Jan 28, 1991
LupinFor profitMKTGJun 9, 2008
MylanFor profitMKTGJun 30, 2011
Natco PharmaFor profitMKTGJun 30, 2011
PerrigoFor profitMKTGJul 23, 2025
PfizerFor profitNDA2Feb 27, 2007
RanbaxyFor profitMKTGMar 6, 2009
Senores PharmsFor profitMKTGJun 18, 2008
TevaFor profitMKTGJun 18, 2008
Watson PharmaceuticalsFor profitMKTGOct 24, 2005
West-Ward PharmaceuticalFor profitMKTGJun 18, 2008
Zydus Discovery DMCCFor profitMKTGSep 2, 2008
Zydus Discovery DMCCFor profitSYNSep 24, 2009